Biotage 将来の成長

OM:BIOT - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2,757	475	538	669	3
12/31/2025	2,457	355	314	477	3
12/31/2024	2,156	255	265	393	3
9/30/2024	2,117	257	243	406	N/A
6/30/2024	2,077	251	261	399	N/A
3/31/2024	1,981	236	268	381	N/A
12/31/2023	1,862	246	193	284	N/A
9/30/2023	1,603	189	148	229	N/A
6/30/2023	1,554	216	147	223	N/A
3/31/2023	1,541	240	220	295	N/A
12/31/2022	1,566	268	271	341	N/A
9/30/2022	1,524	240	285	346	N/A
6/30/2022	1,428	228	285	338	N/A
3/31/2022	1,337	216	290	342	N/A
12/31/2021	1,232	205	297	353	N/A
9/30/2021	1,188	203	273	336	N/A
6/30/2021	1,145	187	256	321	N/A
3/31/2021	1,096	174	222	286	N/A
12/31/2020	1,092	175	218	279	N/A
9/30/2020	1,083	149	213	268	N/A
6/30/2020	1,103	179	221	274	N/A
3/31/2020	1,131	201	211	260	N/A
12/31/2019	1,101	187	166	212	N/A
9/30/2019	1,047	196	145	187	N/A
6/30/2019	997	173	112	158	N/A
3/31/2019	951	170	94	139	N/A
12/31/2018	911	168	108	155	N/A
9/30/2018	865	175	120	170	N/A
6/30/2018	811	162	N/A	149	N/A
3/31/2018	771	148	N/A	168	N/A
12/31/2017	748	139	N/A	169	N/A
9/30/2017	738	122	N/A	145	N/A
6/30/2017	728	118	N/A	145	N/A
3/31/2017	694	105	N/A	131	N/A
12/31/2016	668	93	N/A	139	N/A
9/30/2016	657	96	N/A	130	N/A
6/30/2016	640	87	N/A	133	N/A
3/31/2016	625	78	N/A	133	N/A
12/31/2015	611	73	N/A	120	N/A
9/30/2015	580	83	N/A	116	N/A
6/30/2015	549	75	N/A	98	N/A
3/31/2015	521	75	N/A	94	N/A
12/31/2014	490	65	N/A	81	N/A
9/30/2014	474	53	N/A	72	N/A
6/30/2014	459	49	N/A	70	N/A
3/31/2014	455	46	N/A	52	N/A
12/31/2013	445	41	N/A	57	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BIOTの予測収益成長率 (年間19.5% ) は貯蓄率 ( 1.2% ) を上回っています。

収益対市場: BIOTの収益 ( 19.5% ) はSwedish市場 ( 15% ) よりも速いペースで成長すると予測されています。

高成長収益: BIOTの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: BIOTの収益 ( 12.1% ) Swedish市場 ( -0.04% ) よりも速いペースで成長すると予測されています。

高い収益成長: BIOTの収益 ( 12.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BIOTの自己資本利益率は、3年後には低くなると予測されています ( 11.1 %)。

Biotage 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Price target increased by 9.4% to kr203

Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Price target decreased by 9.2% to kr173

Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Price target increased by 9.6% to kr190

Price target decreased by 7.1% to kr173

Recent updates

Price target increased by 9.4% to kr203

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 48%?

Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Biotage AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025

Price target decreased by 9.2% to kr173

Biotage AB Appoints Nomination Committee

Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Biotage AB (publ) to Report First Half, 2025 Results on Jul 16, 2025

Biotage AB Announces Chief Executive Officer Changes, Effective September 16, 2024

Insider recently bought kr575k worth of stock

KKR Reportedly Mulls Options for Stake in Biotage

KKR Reportedly Mulls Options for Stake in Biotage

Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 9.6% to kr190

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Price target decreased by 7.1% to kr173

Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Biotage AB (Publ) Approves a Dividend, Payable on May 3, 2024

Upcoming dividend of kr1.60 per share

Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to kr173

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Dividend of kr1.60 announced

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 23%

Biotage Appoints Andrew Kellett as CFO

Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Now 23% overvalued after recent price rise

Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

Now 22% undervalued

Biotage AB (publ) Announces CEO Changes

At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Third quarter 2023 earnings: Revenues in line with analyst expectations

Investor sentiment improves as stock rises 27%

Now 20% undervalued after recent price drop

Biotage AB (publ), Annual General Meeting, Apr 25, 2024

Consensus EPS estimates fall by 26%

Biotage AB (Publ) Announces Executive Changes

New minor risk - Insider selling

Insider recently sold kr675k worth of stock

Biotage AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Second quarter 2023 earnings: Revenues exceed analyst expectations

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 26%

Price target decreased by 29% to kr180

Now 23% undervalued

New minor risk - Shareholder dilution

An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

Investor sentiment improves as stock rises 24%

Director recently bought kr2.0m worth of stock

Upcoming dividend of kr1.60 per share at 1.3% yield

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Price target decreased by 12% to kr212

These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Consensus EPS estimates fall by 17%, revenue upgraded

Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Biotage AB (Publ) Proposes Dividend for 2022